Pharmaceutical

Blood cancers dominate CAR-T pipeline

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ Qartemi.

Mar 21, 2025 - 06:00
Blood cancers dominate CAR-T pipeline
Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ Qartemi.
Read the original article

Tags:

Previous Article

Oxford BioTherapeutics and Roche link on antibody cancer treatments

Next Article

Allogeneic cell therapies “poised for prime time” says expert

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Morning Rounds: Teen pregnancies down, but remain higher in the U.S. 

Morning Rounds: Teen pregnancies down, but remain highe...

Dec 15, 2023

Should ACA plans cover weight loss drugs?

Should ACA plans cover weight loss drugs?

Feb 21, 2024

STAT+: Amazon’s chief medical officers on where the company’s health care bets are headed next

STAT+: Amazon’s chief medical officers on where the com...

Sep 8, 2023